Megasulfena Tablet 10mg (Solefenacin Succinate)

Adult dose

The usual recommended dose for adults (including older adults) is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This drug may be taken with or without food and should be swallowed whole with water. Dosage adjustment is required for the following patients. 1. Patients with renal impairment No dosage adjustment is necessary for patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Caution is required in patients with severe renal impairment (creatinine clearance≤30ml/min), and the dose should not exceed 5mg once daily. 2. Patients with hepatic impairment No dosage adjustment is necessary for patients with mild hepatic impairment. Caution is required in patients with moderate hepatic impairment (Child-Pugh class B), and the dose should not exceed 5mg once daily. 3. Patients receiving a strong cytochrome P450 3A4(CYP3A4) inhibitor For patients receiving ketoconazole or another strong CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole), the maximum daily dose should be limited to 5mg.

This medication should not be used by patients with symptoms of urinary retention. Patients with severe gastrointestinal diseases, myasthenia gravis, or narrow-angle glaucoma should also not take this medication. Additionally, patients with allergies to this medication or its ingredients, patients undergoing dialysis, and those with severe liver or kidney dysfunction should not be administered this medication. Patients with genetic issues such as lactose intolerance should also avoid this medication. Caution is advised when using this medication in patients at risk of urinary tract obstruction or suspected gastrointestinal obstruction, as well as in those at risk of decreased gastrointestinal motility. Patients with severe renal or liver dysfunction should have their dosage limited, and caution should be exercised when taken with specific medications. Those with gastroesophageal reflux disease, esophagitis, or autonomic neuropathy should also be administered this medication carefully. This medication may cause dry mouth, constipation, blurred vision, and other symptoms. In severe cases, gastrointestinal issues such as bowel obstruction may occur, so consult a physician immediately if any abnormal symptoms arise. Moreover, serious allergic reactions such as angioedema or anaphylaxis have been reported rarely; if such symptoms occur, cease taking the medication immediately and seek treatment. This medication may cause drowsiness, blurred vision, and fatigue when driving or operating machinery, so caution is needed. Taking this medication with other anticholinergic medications may enhance its effects or increase side effects and may reduce the effectiveness of gastrointestinal motility-promoting drugs. Furthermore, this medication is metabolized by specific hepatic enzymes, so dosage adjustments may be needed when taken with strong CYP3A4 inhibitors. The safety of this medication in pregnant women has not been established, so caution is necessary. Nursing mothers are advised to avoid this medication. The safety and efficacy of this medication in children have not been established, so it should not be used in this population. In the case of overdose, symptoms such as headache, dizziness, drowsiness, and blurred vision may occur, and in severe cases, specialized treatment may be required. If an overdose is suspected, seek medical attention immediately.

• Dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• nausea
• indigestion
• upper abdominal pain
• vomiting
• urinary tract infection

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is best to store it at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a long time.

Appearance

Pale pink, round film-coated tablet

Package unit

100 tablets (10 tablets/PTP × 10)